Connect:        


All Releases
View Summary Intellipharmaceutics Announces First Quarter 2016 Results
Apr 15, 2016
PDF 38.9 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the 28th Annual ROTH Conference
Mar 8, 2016
PDF 18.2 KB Add to Briefcase
View Summary Intellipharmaceutics Announces 2015 Year End Results
Feb 26, 2016
PDF 45.1 KB Add to Briefcase
View Summary Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Keppra XR®
Feb 24, 2016
PDF 18.3 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
Jan 19, 2016
PDF 17.2 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista™ Oxycodone XR
Jan 14, 2016
PDF 20.0 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the Biotech Showcase™
Dec 21, 2015
PDF 17.2 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at the LD Micro Main Event
Nov 24, 2015
PDF 17.5 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at The MicroCap Conference
Oct 27, 2015
PDF 18.0 KB Add to Briefcase
View Summary Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference
Oct 9, 2015
PDF 17.5 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Third Quarter 2015 Results
Oct 9, 2015
PDF 36.3 KB Add to Briefcase
View Summary Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R)
Aug 5, 2015
PDF 18.6 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Second Quarter 2015 Results
Jul 13, 2015
PDF 36.1 KB Add to Briefcase
View Summary Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R)
Jul 8, 2015
PDF 17.4 KB Add to Briefcase
View Summary Intellipharmaceutics Updates Status of Tentative Approvals of Generic Focalin XR(R)
Jun 18, 2015
PDF 16.7 KB Add to Briefcase
View Summary FDA Grants Fast Track Designation for Intellipharmaceutics Rexista(TM) Oxycodone XR Incorporating PODRAS(TM) Technology
May 26, 2015
PDF 19.4 KB Add to Briefcase
View Summary Intellipharmaceutics Announces Agreement to Acquire Real Property that Houses its Manufacturing, R&D and Office Facilities in Toronto, Ontario and Status of 5mg Strength of its Generic Focalin XR(R)
May 25, 2015
PDF 18.1 KB Add to Briefcase
View Summary Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA
May 21, 2015
PDF 18.2 KB Add to Briefcase
View Summary Intellipharmaceutics Reports Director Election Results
Apr 22, 2015
PDF 17.3 KB Add to Briefcase
View Summary Intellipharmaceutics Announces First Quarter 2015 Results
Apr 14, 2015
PDF 33.1 KB Add to Briefcase
Showing 41-60 of 159 Page: 1 2 3 4 5 ... 8  Previous 20 | Next 20
=add release to Briefcase